.
MergerLinks Header Logo

New Deal


Announced

PharmaNutra to acquire Akern from Red Lions, Jacopo Talluri and Liside for $15m.

Financials

Edit Data
Transaction Value£12m
Consideration TypeContingent Deferred Consideration, Cash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Pending

Private

Acquisition

Majority

Italy

Single Bidder

medical devices

Medical Supplies

Friendly

Domestic

Synopsis

Edit

PharmaNutra, a pharmaceutical company, agreed to acquire Akern, a firm engaged in the production and commercialization of medical devices and software for the monitoring of the body composition through bio-impedance techniques, from Red Lions, Jacopo Talluri and Liside for $15m. “The acquisition of Akern represents a turning point for both the companies and a key milestone in the implementation of PharmaNutra’s growth strategy. Akern is a cash generating company with a growing business which will allow the realization of important strategic synergies, starting from 2023, with a boost and diversification of the business lines. Pharmanutra will heavily strengthen its know how benefiting from more than 40 years’ experience of a leading Italian company in the bio-impedance analysis, and it will support Akern in consolidating its presence in the Italian and International markets through our capillary network of distributors," Andrea Lacorte, Pharmanutra Chairman.

Search a database of more than 250,000 verified dealmakers

Receive automated updates on global transactions

Follow the activity, relationships and transactions of top dealmakers

No credit card required

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US